AU1384600A - Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation - Google Patents

Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation

Info

Publication number
AU1384600A
AU1384600A AU13846/00A AU1384600A AU1384600A AU 1384600 A AU1384600 A AU 1384600A AU 13846/00 A AU13846/00 A AU 13846/00A AU 1384600 A AU1384600 A AU 1384600A AU 1384600 A AU1384600 A AU 1384600A
Authority
AU
Australia
Prior art keywords
manifestations
transplantation
rejection
treatment
binding molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13846/00A
Other languages
English (en)
Inventor
Richard K. Howell
Peter Marbach
Andrew Roberts
Max H. Schreier
Manfred Schulz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU1384600A publication Critical patent/AU1384600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU13846/00A 1998-11-23 1999-11-22 Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation Abandoned AU1384600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9825632 1998-11-23
GBGB9825632.4A GB9825632D0 (en) 1998-11-23 1998-11-23 Organic compounds
PCT/EP1999/008988 WO2000030679A1 (en) 1998-11-23 1999-11-22 Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation

Publications (1)

Publication Number Publication Date
AU1384600A true AU1384600A (en) 2000-06-13

Family

ID=10842889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13846/00A Abandoned AU1384600A (en) 1998-11-23 1999-11-22 Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation

Country Status (6)

Country Link
US (2) US20010041179A1 (enExample)
EP (1) EP1131098A1 (enExample)
JP (1) JP2002530354A (enExample)
AU (1) AU1384600A (enExample)
GB (1) GB9825632D0 (enExample)
WO (1) WO2000030679A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US8252126B2 (en) * 2004-05-06 2012-08-28 Global Advanced Metals, Usa, Inc. Sputter targets and methods of forming same by rotary axial forging
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
ATE222502T1 (de) * 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Also Published As

Publication number Publication date
JP2002530354A (ja) 2002-09-17
WO2000030679A1 (en) 2000-06-02
US20010041179A1 (en) 2001-11-15
EP1131098A1 (en) 2001-09-12
GB9825632D0 (en) 1999-01-13
US20080286281A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
AU2003284123A1 (en) Composition and filter system using the said composition
AU1803601A (en) Methods and compositions for the introduction of molecules into cells
AU4474700A (en) Filter media
SG85153A1 (en) Polishing composition and polishing process
EP1110590A3 (de) Flüssigkeitsfilter mit Ablass für Flüssigkeitsrückstände
AU2862100A (en) Materials and methods for the purification of polyelectrolytes
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU5064699A (en) Composition containing bamboo charcoal and carrier having the same
AU5547000A (en) Novel treatment
AU5894900A (en) Novel molecules of the card-related protein family and uses thereof
AU2035401A (en) Lubricant combination and process for the preparation thereof
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
AU2837301A (en) Use of polymeric material in the treatment of hard surfaces
AU6056500A (en) Process and composition for temporarily suppressing pain
EP1147213A4 (en) RGS-CONTAINING MOLECULES AND THEIR USE
AU1384600A (en) Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation
AU5056099A (en) Compounds for use in the treatment of inflammation
AU1590201A (en) Compositions and methods for treating autoimmune diseases and transplant rejections
AU1160201A (en) Filter
AU7450900A (en) Polishing composition and method
AU2021601A (en) Composition for the treatment of dandruff
AU4556800A (en) Novel treatment
AU2587399A (en) Human transport-associated molecules
AU5134600A (en) Full-length molecules expressed in human tissues
AU2663300A (en) Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase